These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 458486

  • 1. Tiapride in levodopa-induced involuntary movements.
    Lees AJ, Lander CM, Stern GM.
    J Neurol Neurosurg Psychiatry; 1979 Apr; 42(4):380-3. PubMed ID: 458486
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Tiapride in levodopa-induced involuntary movements.
    Mejer Nielsen B.
    Acta Neurol Scand; 1983 Jun; 67(6):372-5. PubMed ID: 6351529
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Therapeutical approach to involuntary movements (author's transl)].
    Allain H, Sabouraud O.
    Sem Hop; 1983 Jun; 55(5-6):262-4. PubMed ID: 219537
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.
    Johnston TH, Versi E, Howson PA, Ravenscroft P, Fox SH, Hill MP, Reidenberg BE, Corey R, Brotchie JM.
    Neuropharmacology; 2018 Mar 15; 131():116-127. PubMed ID: 29197517
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.
    Svenningsson P, Rosenblad C, Af Edholm Arvidsson K, Wictorin K, Keywood C, Shankar B, Lowe DA, Björklund A, Widner H.
    Brain; 2015 Apr 15; 138(Pt 4):963-73. PubMed ID: 25669730
    [Abstract] [Full Text] [Related]

  • 11. A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease.
    Tison F, Keywood C, Wakefield M, Durif F, Corvol JC, Eggert K, Lew M, Isaacson S, Bezard E, Poli SM, Goetz CG, Trenkwalder C, Rascol O.
    Mov Disord; 2016 Sep 15; 31(9):1373-80. PubMed ID: 27214664
    [Abstract] [Full Text] [Related]

  • 12. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification.
    Luquin MR, Scipioni O, Vaamonde J, Gershanik O, Obeso JA.
    Mov Disord; 1992 Sep 15; 7(2):117-24. PubMed ID: 1350058
    [Abstract] [Full Text] [Related]

  • 13. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F, Rascol O, Destee A, Hattori N, Hauser RA, Lang AE, Poewe W, Stacy M, Tolosa E, Gao H, Nagel J, Merschhemke M, Graf A, Kenney C, Trenkwalder C.
    Mov Disord; 2013 Nov 15; 28(13):1838-46. PubMed ID: 23853029
    [Abstract] [Full Text] [Related]

  • 14. The pharmacological therapeutic management of levodopa-induced dyskinesias in patients with Parkinson's disease.
    Rascol O.
    J Neurol; 2000 Apr 15; 247 Suppl 2():II51-7. PubMed ID: 10991666
    [Abstract] [Full Text] [Related]

  • 15. Metoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesias.
    Tarsy D, Parkes JD, Marsden CD.
    J Neurol Neurosurg Psychiatry; 1975 Apr 15; 38(4):331-5. PubMed ID: 1095689
    [Abstract] [Full Text] [Related]

  • 16. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
    Bezard E, Brotchie JM, Gross CE.
    Nat Rev Neurosci; 2001 Aug 15; 2(8):577-88. PubMed ID: 11484001
    [Abstract] [Full Text] [Related]

  • 17. A Phase Ib Randomized Controlled Study to Evaluate the Effectiveness of a Single-Dose of the NR2B Selective N-Methyl-D-Aspartate Antagonist MK-0657 on Levodopa-Induced Dyskinesias and Motor Symptoms in Patients With Parkinson Disease.
    Herring WJ, Assaid C, Budd K, Vargo R, Mazenko RS, Lines C, Ellenbogen A, Verhagen Metman L.
    Clin Neuropharmacol; 2017 Aug 15; 40(6):255-260. PubMed ID: 29059133
    [Abstract] [Full Text] [Related]

  • 18. The spectrum of levodopa-induced dyskinesias.
    Fahn S.
    Ann Neurol; 2000 Apr 15; 47(4 Suppl 1):S2-9; discussion S9-11. PubMed ID: 10762127
    [Abstract] [Full Text] [Related]

  • 19. The impact of treatment with levodopa on Parkinson's disease.
    Shaw KM, Lees AJ, Stern GM.
    Q J Med; 1980 Apr 15; 49(195):283-93. PubMed ID: 7465763
    [Abstract] [Full Text] [Related]

  • 20. A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia.
    Trenkwalder C, Berg D, Rascol O, Eggert K, Ceballos-Baumann A, Corvol JC, Storch A, Zhang L, Azulay JP, Broussolle E, Defebvre L, Geny C, Gostkowski M, Stocchi F, Tranchant C, Derkinderen P, Durif F, Espay AJ, Feigin A, Houeto JL, Schwarz J, Di Paolo T, Feuerbach D, Hockey HU, Jaeger J, Jakab A, Johns D, Linazasoro G, Maruff P, Rozenberg I, Sovago J, Weiss M, Gomez-Mancilla B.
    Mov Disord; 2016 Jul 15; 31(7):1049-54. PubMed ID: 26990766
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.